In 2005, there were 580 000 total hip or knee replacements (THR or TKR) performed in the US, [1] and that number is projected to increase to 4.5 million by 2030. [2] Although THR and TKR are generally safe procedures, [3] they have been identified [4] as high-risk events for venous thromboembolism (VTE), which includes deep venous thrombosis (DVT) and pulmonary embolism (PE). For almost 20 years, physicians have been offering pharmacological prophylaxis to patients undergoing THR and TKR; however, uncertainty exists about the optimal pharmacological regimen for prophylaxis.
Guidelines [4] published by the American College of Chest Physicians (ACCP) in 2008 support using potent anticoagulant regimens with agents such as fondaparinux sodium, low-molecularweight heparin (LMWH) and warfarin (target international normalized ratio [INR] 2-3), and discourage acetylsalicylic acid (aspirin) therapy alone. In contrast, guidelines [5] by the American Academy of Orthopaedic Surgeons (AAOS) support the use of aspirin or a lower-potency warfarin regimen (INR < 2) in addition to LMWH and fondaparinux, stating that the latter agents do not offer increased protection against PE but substantially raise the rate of bleeding complications. New oral anticoagulants such as dabigatran etexilate, a direct thrombin inhibitor, are expected to gain US FDA approval within the next several months and it is anticipated that they too will be supported by the above professional societies. 522 Kapoor et al.
Several studies have attempted to address these risk-benefit and also cost issues using decision analysis methodology. Some studies [6] [7] [8] indicate that the newer regimens are cost effective in preventing VTE, while others [9] do not. Individual study results vary depending on the setting, economic perspective (e.g. groups for which cost and effects will be aggregated -patients, payers or others), horizon (time course over which cost and effectiveness information was assessed) and effectiveness outcome analysed (e.g. VTE events averted, life-years gained, QALYs gained). Measuring effectiveness in QALYs, particularly over a horizon of ‡1 year, permits comparison of cost effectiveness of interventions across diseases, but some authors may choose not to measure QALYs because their focus resides in the economics related to the period immediately following surgery. To more meaningfully compare VTE prophylaxis regimens, we systematically reviewed recently published studies that evaluated the cost effectiveness of the different pharmacological options in patients undergoing THR and TKR. We abstracted information about cost and effects for both a short and long horizon. In each case, we calculated the incremental cost-effectiveness ratios (ICERs) using our abstractions and then converted our estimates into $US, year 2009 values.
Literature Review

Study Selection
Using published recommendations [10] for identification of cost-effectiveness studies, we searched MEDLINE (January 1997 to October 2009), EMBASE (January 1997 to June 2009) and the UK NHS Economic Evaluation Database [11] (1997 to October 2009) [for search strategies, see Appendix 1 in the Supplemental Digital Content 1, http://links.adisonline.com/PCZ/A73]). We also searched the bibliographies of included studies.
We included studies that evaluated the cost effectiveness of pharmacological agents in patients undergoing THR or TKR. Specifically, we focused our search on recent (1997 to October 2009) studies published in English that contained complete documentation of methods (as compared with abstracts or brief reports), had discrete information available for TKR or THR (i.e. not combined with other orthopaedic surgeries) and contained enough information to calculate an ICER for at least one of five important comparisons: (i) anticoagulants (fondaparinux, LMWH, warfarin) versus aspirin; (ii) LMWH versus warfarin; (iii) fondaparinux versus LMWH; (iv) comparisons including new oral anticoagulants; and (v) extended-duration prophylaxis ( ‡3 weeks with any agent) versus short-duration prophylaxis (<3 weeks with any agent). We did not analyse information about regimens not routinely recommended as sole therapy by the ACCP or AAOS. These include unfractionated heparin, parenteral thrombin inhibitors or nonpharmacological means such as intermittent pneumatic compression or graduated stockings. Two authors (AK and NR) evaluated each study for inclusion. Disagreements were resolved by discussion.
Study Abstraction and Quality Assessment
We derived an abstraction instrument based on the recommendations of the Panel on CostEffectiveness in Health and Medicine. [12] [13] [14] Two abstractors (NR and WC) assisted the primary author (AK) in recording, in duplicate, the description of the study setting, cohort age, economic perspective and presence of pharmaceutical industry sponsorship.
To summarize the cost-effectiveness information of our five main comparisons, we abstracted data on the incremental cost and effectiveness for both a short and a longer horizon when available. The horizon represents the period of time over which costs and effectiveness are aggregated. For certain diseases, such as the common cold, a short-horizon analysis may suffice. In other cases, long-term consequences must be accounted for, even for short-term interventions. [12] [13] [14] For the short horizon, we abstracted data on the projected costs incurred and VTE events avoided for the period closest to 90 days from surgery. For the purpose of calculating effectiveness, we Prophylaxis for Venous Thromboembolism 523 abstracted data on the combined incidence of DVT and PE that would be detected in routine clinical practice. If a study did not report such an outcome, we also accepted the incidence of radiographically detected events and noted the distinction. If effectiveness was defined only by life-years or QALYs, we recorded that information.
For the long horizon, we accepted any information that projected the cost and effectiveness for ‡1 year. We abstracted effectiveness information by prioritizing abstraction of the outcome of QALYs or unadjusted life-years.
For each study with missing information about drug regimen, dosage, duration of therapy, horizon of analysis, major bleeding rate, DVT, PE and death rate, we contacted corresponding authors first by email and then by letter. If the authors did not respond, we recorded the information as 'not reported'.
We adjusted all cost information to $US, year 2009 values, by inflating or deflating to the year 2005 according to readily available consumer price indices for each country, [15, 16] converting to $US via WHO purchasing power parity indices, [17] and then inflating to $US using the Bureau of Labor Statistics consumer price calculator. [18] This approach followed the example of Bachmann.
[19]
Study Quality
To assess study quality, we created an instrument adapted from 'Drummond's list' [20] and one other instrument from Brauer et al. [21] These included items about the use of cost data from a randomized controlled trial or other primary source, use of efficacy data from pooled results of a systematic review, identification of credible sources for all input parameters, appropriate calculation of an ICER and use of comprehensive one-way sensitivity analyses. The ICER is an expression of how much additionally it costs (in dollars) to achieve an additional unit of benefit (e.g. 1 more QALY). Policy makers are interested in the ICER value because it facilitates determination about whether newer, more effective interventions represent good value compared with existing, less expensive programmes. [22] The threshold for adoption in the US is thought to be somewhere between $US20 000 and $US100 000 per QALY gained. [23] We also recorded quality items specific to VTE (including assessment of joint function following haemarthrosis, propagation of asymptomatic DVT to symptomatic PE, incidence of postthrombotic syndrome, costs of major and minor bleeding) and future costs related to VTE (including blood monitoring and physician visits). Studies ignoring downstream bleeding consequences could make newer, more potent regimens appear more cost effective, whereas studies ignoring downstream costs of treating VTE will bias our interpretation in the other direction. We did not specifically document if individual studies included death costs related to VTE or bleeding. On the whole, death events were rare and the associated costs would be largely paid by the family of the patient and not the institution or health system, which was the economic perspective chosen by all but three of the studies analysed.
We did not pool the results of individual studies given the various modelling assumptions adopted by each author. Instead, we qualitatively compared studies to determine trends in the cost effectiveness of certain regimens compared with others.
Search Results
We identified 370 titles and abstracts meeting our search criteria. Of these, 56 were relevant and were entered for full-text review. Of these, 33 studies met all inclusion criteria [6] [7] [8] [9] (figure 1).
Most studies were set in the US (14 of 33) [27] [28] [29] [31] [32] [33] [34] [35] [36] [37] 40, 41, 43, 45] or Europe (14 of 33) . [6] [7] [8] 25, 26, 30, 38, 44, [46] [47] [48] [49] 51, 52] Twenty studies [6, 7, 24, [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] 40, 41, [43] [44] [45] [46] adopted an institutional perspective; only three [9, 48, 49] adopted a societal perspective. Ten studies [6, 8, 24, 28, 31, 36, 46, 47, 50, 52] reported pharmaceutical company sponsorship.
There was substantial variation in the quality of reporting. Only six of the 33 studies reported performing a systematic review and meta-analysis of 524 Kapoor et al.
efficacy data. [9, 26, 28, 35, 36, 50] In addition, only 13 studies [6, 9, 25, 26, 28, [32] [33] [34] [35] 44, 47, 48, 52] documented comprehensive use of one-way sensitivity analysis. Only four of 33 studies [9, 28, 49, 50] measured effectiveness in QALYs to at least the 1-year horizon (table I, and table A1 in the Supplemental Digital Content).
Anticoagulants versus Aspirin
We included two studies [24, 25] with three comparisons of an anticoagulant with aspirin (table II) . In all three comparisons, results were available for THR exclusively. Sarasin and Bounameaux [25] found that the ICER was $US1700 per VTE avoided for 4 weeks of warfarin compared with aspirin and $US1300 per VTE avoided for 4 weeks of LMWH compared with aspirin. There was no apparent pharmaceutical company sponsorship for that study. The final comparison, sponsored by sanofi-aventis, the manufacturer of enoxaparin, was set in South Africa and reported an ICER of $US7200 per VTE avoided for 10 days of enoxaparin compared with 10 days of aspirin.
Low-Molecular-Weight Heparin (LMWH) versus Warfarin
We included 15 studies with comparisons of LMWH and warfarin [9, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] 50] (table III) . Twelve compared these agents in patients receiving THR. Of those documenting a short-horizon costeffectiveness result, three [25, 34, 50] found that the ICER for LMWH was £$US2000 per VTE avoided compared with warfarin. In two other studies, [28, 29] LMWH cost an additional $US2100 per VTE avoided. In a sixth study, [32] LMWH cost $US5200 per VTE avoided. In the next study, [9] LMWH cost $US109 000 per VTE avoided. This study by Skedgel et al. [9] examined 4 additional weeks (in addition to the hospital period) of LMWH compared with 4 additional weeks of warfarin. It found that the cost, in Canada, would be almost 10-fold higher for LMWH given the significant proportion of patients (39% at Citations eliminated for duplication of previous analysis (n = 2)
Did not contain a full methods section (n = 3)
Did not conduct an original analysis (n = 3)
Did not contain discrete data on joint replacement (n = 2)
Did not contain English language text (n = 1)
Did not contain enough information to calculate an incremental cost-effectiveness ratio (n = 1)
Did not include a comparison between an anticoagulant and ASA, LMWH and warfarin, fondaparinux and LMWH, new oral anticoagulant or extended-and short-duration prophylaxis (n = 11) 
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baseline) that would require daily nursing supervision of LMWH injection in their homes than the same proportion that would require weekly home phlebotomy for monitoring INR while using warfarin. In the remaining four studies of short horizon, [26, 30, 31, 36] warfarin dominated LMWH. In two studies with a long horizon, results conflicted, with one study [28] finding that LMWH dominated warfarin while the other [37] found the opposite.
In comparisons that analysed cost effectiveness in the setting of TKR (or TKR cases combined with THR cases), LMWH dominated or cost <$US2000 per VTE avoided in five studies. [27, [33] [34] [35] 50] In the final study, [26] warfarin dominated LMWH.
Eight of 15 studies comparing LMWH with warfarin reported some pharmaceutical company sponsorship, grant support or involvement of pharmaceutical company consultants. In each case, the pharmaceutical company was the manufacturer of LMWH; either sanofi-aventis, Pfizer or a company that merged with these two. All but two [31, 36] of these eight found favourable costeffectiveness ratios for LMWH. The two studies [9, 26] by government agencies indicated that LMWH was either poor value for its cost or was dominated by warfarin.
Fondaparinux versus LMWH
We included ten studies with comparisons of fondaparinux and LMWH [7, 8, [38] [39] [40] [41] [42] [43] [44] [45] (table IV) . Nine of ten analysed prophylaxis for THR. Six studies [7, 8, 38, 39, 41, 45] analysed cost effectiveness over a short horizon. In all six, fondaparinux dominated or cost £$US1300 per VTE avoided. In four studies with a long horizon, fondaparinux dominated LMWH. In a fifth, LMWH cost $US40 per VTE avoided.
Of the eight studies reporting cost-effectiveness results for TKR, [7, 8, 38, 39, [42] [43] [44] [45] all but one found that fondaparinux dominated LMWH over the short and long horizon. In this study, [42] fondaparinux cost an additional $US660 per VTE avoided.
Among the ten studies comparing fondaparinux with LMWH, a pharmaceutical company sponsored one and supported five more through c Derived from quality scales published separately by Drummond et al. [20] and Brauer et al. [21] d Of a total of seven studies.
ICER = incremental cost-effectiveness ratio; LMWH = low-molecularweight heparin.
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grants. In each case the sponsor or grantor was sanofi-aventis, the manufacturer of enoxaparin (the inferior comparator). Each result demonstrated good value with dominance by the use of fondaparinux.
Comparisons Including New Oral Anticoagulants
Only two studies to date have made comparisons with new oral anticoagulants (see table V). In the only one that made this comparison in patients undergoing THR, Wolowacz et al. [52] found that dabigatran dominated LMWH over a 60-year horizon (equivalent to a lifetime analysis, given the elderly age of the average patient undergoing THR).
In the setting of TKR, McCullagh et al., [51] found that, in the short horizon of 180 days, rivarobaxan dominated both LMWH and dabigatran; dabigatran cost an additional $US750 per VTE avoided compared with LMWH. In the long horizon, Wolowacz et al. [52] found that dabigatran dominated LMWH.
The study by Wolowacz et al. [52] was sponsored by Boehringer Ingelheim, the manufacturer of dabigatran, whereas McCullagh et al. [51] reported no sponsorship or support.
Extended-Duration versus Short-Duration Prophylaxis
We found nine studies [6, 9, 30, [46] [47] [48] [49] [50] [51] with comparisons of extended-versus short-duration prophylaxis in patients undergoing THR (table VI) . Among short-horizon results, three studies [30, 46, 51] with five comparisons found that extendedduration therapy after THR either dominated short-duration prophylaxis or the ICER was <$US120 per VTE avoided. In Skedgel et al., [9] extended-duration warfarin prophylaxis cost an additional $US3200 per VTE avoided but extended-duration LMWH cost an additional $US27 400 per VTE avoided. In five other studies, the ICER for extended-duration therapy was between $US7800 and $US13 200 per VTE avoided. In McCullagh et al., [51] dabigatran administered for 35 days cost $US730 000 per VTE Prophylaxis for Venous Thromboembolism 527 Among two THR studies with long-horizon results available, Bischof et al. [6] found that extended-duration fondaparinux dominated shortduration fondaparinux. Haentjens et al. [49] found that extended-duration enoxaparin cost an additional $US9300 per QALY gained compared with short-duration enoxaparin.
We found only two studies for TKR. At a 35-day horizon, Dranitsaris et al. [50] found that the extended-duration dalteparin cost an additional $US14 600 per VTE compared with shortduration warfarin and $US60 000 per VTE compared with short-duration dalteparin. At a 1-year horizon, Haentjens et al. [49] found that extended-duration enoxaparin cost an additional $US73 300 per QALY gained compared with short-duration enoxaparin.
Six of the nine studies comparing extendedwith short-duration therapy included pharmaceutical company sponsorship or grant support. There was no clear trend among the results with respect to the presence of sponsorship, although two of the three studies sponsored exclusively by a government agency found that extendedduration therapy with LMWH or dabigatran delivered improved effectiveness at a relatively high cost ($US27 400-730 000 per VTE avoided). As mentioned above, the third study by Haentjens et al. [49] found that extended-duration LMWH was clearly cost effective after THR but poorer value after TKR.
Discussion
Although multiple VTE prophylaxis regimens are supported by the ACCP and the AAOS, our systematic review suggests that not all of them may be cost effective relative to other regimens. There was no consensus about the cost effectiveness of LMWH compared with warfarin. In contrast, fondaparinux dominated LMWH in nearly every comparison we found. Extendedduration prophylaxis with LMWH after THR appeared to be cost effective, with multiple [18] d DVT rate (i.e. symptomatic vs radiographic) not specified. e ICER compares extended LMWH with extended-duration warfarin. bid = twice daily; DVT = deep venous thrombosis; ICER = incremental cost-effectiveness ratio; INR = international normalized ratio; NR = not reported; od = once daily; PE = pulmonary embolism; VTE = venous thromboembolism. Comparisons of our work with previous reviews of the economic literature are limited by differences in type of surgery included and publication dates of the included articles. Sullivan et al. [53] summarized the prophylaxis literature between 1984 and 2000 and found that most studies presented consistent findings, including that LMWH is cost effective compared with warfarin. Our results do not support this conclusion. Sullivan et al. [53] based their conclusions on many studies that we excluded because they were published prior to 1997 or that included outcomes from patients undergoing hip fracture surgery. We believe temporal trends [54, 55] in the care of THR and TKR necessitated excluding earlier studies. We also felt that hip fracture surgery identified a distinctive patient population with respect to cost, risk and benefit issues. [4] Similar to our findings, Sullivan et al. [53] also found that extended-duration LMWH was generally cost effective compared with short-duration therapy.
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Ivanovic et al. [56] summarized the literature on fondaparinux. These authors concluded that fondaparinux was more cost effective than LMWH (enoxaparin) 40 mg daily initiated preoperatively but less cost effective than LMWH 30 mg twice daily initiated postoperatively. Our review did not specifically compare the cost effectiveness of regimens with LMWH initiated at different times but we found that fondaparinux dominated LMWH in all but one when considering the longer horizon. LMWH dosages in the included studies were evenly distributed between 40 mg daily and 30 mg twice daily. Ivanovic et al. [56] also reported not being able to calculate ICERs for two studies, whereas we were able to calculate them based on data presented in tables included by the study authors. 
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Wolowacz et al. [57] also published a review discussing the evolution of model building over a 20-year time span (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . In terms of quality, the findings of that review were generally consistent with the abstractions we performed, particularly with respect to the paucity of studies measuring QALYs over a sufficiently long period. Unlike their review, we abstracted cost and effect information and independently calculated ICERs for each comparison discussed. We converted costs to $US, year 2009 values and measured effects in common units (total VTE events avoided for short-horizon studies and QALYs for long-horizon studies). This facilitated comparisons between the multiple regimens supported by major professional societies.
The most salient finding of our review is that fondaparinux dominates LMWH; however, these results should be interpreted cautiously. There have been only four randomized controlled trials comparing fondaparinux with enoxaparin [58] [59] [60] [61] and only one [58] involved patients with TKR surgery. A summary estimate of risk calculated by Turpie et al. [62] suggested that fondaparinux offers a 55% reduction in the odds of venographic VTE but no difference in the incidence of symptomatic VTE at postoperative day 11 when screening venography was performed. The studies of cost effectiveness evaluating fondaparinux generally extrapolated these short-horizon venographic rates to estimate the number of symptomatic VTE events. Recent evidence [63] suggests that the ratio of asymptomatic venographic DVT rate to symptomatic DVT rate is between 3 and 7 for THR and between 15 and 24 for TKR. However, these ratios came from trials using enoxaparin only. Although they do not address this point specifically for fondaparinux, the 2008 ACCP guidelines [4] state that initial efficacy studies using venographic endpoints should be followed with trials that use symptomatic (and objectively confirmed) VTE as endpoints.
There is less conclusive evidence about the duration of prophylaxis, although extended prophylaxis with LMWH appears cost effective compared with short-duration therapy in the case of THR surgery. Authors of cost-effectiveness studies included in this review generally summarized efficacy of extended-duration prophylaxis with LMWH using one or more of the seven [18] DVT = deep venous thrombosis; ICER = incremental cost-effectiveness ratio; LMWH = low-molecular-weight heparin; PE = pulmonary embolism; VTE = venous thromboembolism.
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Kapoor et al. randomized controlled trials [64] [65] [66] [67] [68] [69] [70] that reported on the efficacy of extended-duration prophylaxis. At least two of these trials [64, 65] did not require venography at the time of discharge from the hospital, permitting assessment of symptomatic VTE rates from 4 to 7 weeks after operation. We cannot draw firm conclusions on the question of extended duration versus short duration of therapy with other agents that have not been studied extensively. Our review also suggests that there is insufficient cost-effectiveness evidence to support extended prophylaxis for TKR. The most recent update of the ACCP guidelines ''recommends'' extended prophylaxis for THR and ''suggests'' extended prophylaxis for TKR.
Limitations to our work include differences in economic perspective and setting. As our results overwhelmingly suggest that fondaparinux dominates LMWH, we believe our conclusions are sound for this comparison, keeping in mind the absence of trial data measuring symptomatic endpoints. The economic perspective did not appear to explain the variations in results found, but we did not have sufficient numbers of studies within each major comparison to make firm statements about the influence of individual differences in analytic methods. Although we converted from foreign currencies to $US using purchasing power parity, cost structures between countries may not be comparable. [71] We also acknowledge the potential bias exerted by pharmaceutical company sponsorship of multiple studies. This bias could have played a role in the comparisons between LMWH and warfarin and extended-versus short-duration therapy. They do not appear to have played a role in the comparisons including fondaparinux. Multiple studies sponsored by the manufacturer of LMWH found fondaparinux to dominate LMWH. However, we generally did not have sufficient numbers of studies within each comparison type to determine if variation in study results was related to pharmaceutical company sponsorship.
Another major limitation is that there is no established threshold for declaring a prophylaxis regimen cost effective when disease-based units are used to express effectiveness. The QALY permits comparison of the value of interventions across diseases given that the utilities that are used to calculate them are standardized to estimates between 0 and 1, where 1 represents perfect health and 0 represents death. Another limitation includes absence of costeffectiveness analyses about certain comparisons such as fondaparinux versus warfarin, fondaparinux versus aspirin, and low-intensity warfarin (INR < 2) versus any of the other regimens. We also acknowledge the possibility of English language and publication bias, as with any systematic review.
The demand for cost-effectiveness research is growing at a fervent pace. In early 2009, the US Government dedicated $US1.1 billion to comparative effectiveness research, including costeffectiveness research. [72] The US Centers for Disease Control adopted the results of costeffectiveness research when it prepared guidelines [73] about screening for HIV infection. Similarly, the US Preventive Services Task Force incorporated model results when it updated its most recent colorectal cancer screening recommendations. [74] As the demand for cost-effectiveness work grows, the need to be able to summarize and standardize the information will also grow. Our work was a comprehensive systematic review of the cost-effectiveness literature regarding VTE prophylaxis for patients undergoing total joint replacement. In addition, we improved upon previous reviews by standardizing cost-effectiveness information to a common currency and effectiveness unit.
Conclusions
We found that fondaparinux dominated LMWH in virtually all studies we analysed, but firm conclusions cannot be made until trial data are available that measure symptomatic VTE rates. Extended-duration LMWH prophylaxis also appears cost effective compared with shortduration prophylaxis in the case of THR. There is limited evidence to determine the cost effectiveness of other regimens, including extendedduration fondaparinux, extended-duration LMWH after TKR, prophylaxis with new oral anticoagulants, low-intensity warfarin therapy or aspirin.
These knowledge gaps represent important areas for future research.
